Furin/PACE/SPC1: A convertase involved in exocytic and endocytic processing of precursor proteins  by Denault, Jean-Bernard & Leduc, Richard
FEBS 16558 
Minireview 
FEBS Letters 379 (1996) 113-l 16 
Furin/PACE/SPC 1: a convertase involved in exocytic and endocytic 
processing of precursor proteins 
Jean-Bernard Denault, Richard Leduc* 
Department of Pharmacology, Faculty of Medicine, UniversitP de Sherbrooke, Sherbrooke. Quebec. Canada JlN SN4 
Received 21 November 1995 
Abstract One of the most exciting breakthroughs of the 90’s in 
the fields of biochemistry, cell biology and neuroendocrinology is 
the identification of a novel family of proteolytic enzymes called 
mammalian subtilisin-like convertases. This family is comprised 
so far of seven distinct endoproteases responsible for the prote- 
olytic excision of biologically active polypeptides from inactive 
precursor proteins. Six years after the initial observation of a 
structural conservation between a characterized yeast enzyme 
(kexin) and a human gene product (furin), it is now well accepted 
that one of these convertases, furin, has the enzymatic capabilities 
to efficiently and correctly process a great variety of precursors. 
Furin’s ability to cleave precursors within both the exocytic and 
endocytic pathways will require sustained efforts in order to delin- 
eate all of its physiological roles. 
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1. Introduction 
Biologically active polypeptides act as intercellular messen- 
gers of information (neuropeptides, hormonal peptides), direct 
many cellular activities (growth factors, enzymes, receptors) 
and are involved in the pathogenicity associated with certain 
viruses (viral glycoproteins) or bacteria (toxins). Since many of 
these polypeptides are initially synthesized as large, inactive 
precursors or pro-proteins, a common cellular mechanism must 
function to release the bioactive segment of the protein. This 
mechanism is the proteolytic cleavage of the precursor by cellu- 
lar endoproteases which usually takes place at specific pairs of 
basic amino acids like ArggArg or Lys-Arg [ 11. This processing 
event is found in bacteria, fungi, yeast, invertebrates and mam- 
mals and occurs both within the exocytic (secreted and mem- 
brane proteins) as well as the endocytic pathway (uptake, proc- 
essing and degradation of proteins). At the end of 1989, it was 
observed that the yeast enzyme, kexin, which had been charac- 
terized as a Ca*‘-dependent serine protease able to cleave yeast 
pro-a factor and pro-killer toxin, had a high amino acid se- 
quence similarity at its catalytic site with a human gene product, 
furin (also called SPCl or PACE for paired basic amino acid 
cleaving enzyme) [2]. The corresponding gene, FUR, was the 
upstream region of the fes/fps proto-oncogene and had been 
partially sequenced three years before [3]. 
This was the beginning of an extensive search for other pro- 
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teases of this family. Presently, there are seven distinct conver- 
tases that we can tentatively assign to four subgroups based on 
their tissue localization; the furin and PC7 subgroup has a 
ubiquitous distribution, the PACE4 and PC5 subgroup has a 
distribution which overlaps that of the previous enzymes but 
not in all cases, the PC1 (also called PC3) and PC2 subgroup 
is restricted to endocrine and neuroendocrine cells while PC4 
is limited to round spermatids [4]. Although these enzymes may 
diverge in their tissue distribution and in their cellular localiza- 
tion, one common thread resides in their specificity to process 
protein precursors at some single basic residues and/or selective 
pairs of basic amino acids permitting release of the active pep- 
tide. Here, we will focus on one of these convertases, furin. 
2. Tissue and sub-cellular localization of furin 
Furin (EC 3.4.21.85) is the first and so far the best character- 
ized enzyme of the mammalian subtilisin-like family of conver- 
tases. Northern blot analysis has demonstrated that the major 
4.4 kb furin transcript is ubiquitously distributed [4]. In human, 
this mRNA gives rise to a type I membrane-bound protein 
localized mainly in the trans-Golgi network (TGN). Recent 
reports have demonstrated that furin can translocate between 
the cell surface and the TGN [5,6]: this translocation event is 
highly reminiscent of the retrieval pathway observed in the case 
of the TGN38 protein [7]. Translocation to the cell surface and 
from early endosomes back to the TGN may depend on two 
routing signals found in the cytoplasmic domain of the enzyme 
[8]. The first of these, the CPSDSEEDEG sequence (residues 
771-780), contains a casein kinase II phosphorylation motif 
(S/T-DIE-DIE-D/E) which may be subjected to different phos- 
phorylation patterns at the Ser773 and Ser775 residues [9, lo]. The 
result of these phosphorylation/dephosphorylation events 
would be the routing of furin towards specific organelles, either 
the TGN or the cell surface via endosomes or granules. The 
other targeting signal is the YKGL sequence (residues 757- 
760), a determinant for routing furin to the endosomes [8]. In 
light of these observations, it is interesting to note that proteins 
containing the YXX0 motif, where 0 is a bulky hydrophobic 
side chain, have recently shown to bind medium chains of 
clathrin-associated protein complexes [l 11. The physiological 
role of such translocation events is unknown but cell surface 
furin may mediate processing of bacterial toxin precursors as 
well as viral fusion protein precursors (see Table l), both of 
which are detrimental to the host cell. It had been originally 
suggested that the FUR gene product could act as a receptor 
molecule due to the fact that it contains a cysteine-rich region, 
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a motif found in the tumor necrosis factor receptor, insulin 
receptor and epidermal growth receptor molecules [12]. The 
recent observations of a furin-like protein in the cellular mem- 
branes of tomato leaves which would interact with systemin 
[ 131, a powerful inducer of proteinase inhibitor synthesis, could 
lend weight to this hypothesis. 
Once furin has reached the cell membrane it may also be 
further processed either by an autocatalytic process or via an- 
other protease. This possibility is brought about by evidence 
demonstrating the presence of a shortened form of the enzyme 
in the media of cells overexpressing native furin [14] although 
the likelihood exists that overexpression systems may artefactu- 
ally be responsible for the production of this secreted product. 
More experiments are needed to measure levels of furin outside 
the cell which may lead to the elucidation of the possible phys- 
iological role of this enzyme in cleavage of extracellular sub- 
strates. 
3. Biochemical and enzymatic features of furin 
The human FUR gene, mapped to chromosome lSq25-q26 
[3,4], was cloned in 1990 from a cDNA library constructed from 
a human liver cell line, HepG2 cells [15,16]. This led to the 
identification of Rattus norvegicus [17], A4us musculus [18], 
Drosophila melanogaster [19,20], Caenorhabditis elegans [21], 
Aplysia californica [22], Xenopus laevis [23], Lymnaea stagnalis 
[24], Bos taurus [6], Cricetulus griseus [25] enzymes correspond- 
ing to or closely related to furin. 
Upon examination of the human furin cDNA sequence, we 
can predict a translation product of 794 amino acids. As de- 
picted in Fig. 1, the general organization of the various domains 
of this Ca”-dependent protease is as follows: (1) a signal pep- 
tide enabling access to the secretory pathway; (2) a pro-region 
which may act as a pseudo-chaperone and when removed from 
the zymogen leads to enzyme activation; (3) a catalytic domain 
whose structure is closely related to subtilisin-like enzymes; 
(4) a homo or P-domain whose partial or total integrity might be 
necessary for proper enzymatic activity and which contains a 
‘receptor like’ cysteine-rich region; (5) a hydrophobic trans- 
membrane spanning domain anchoring the enzyme to mem- 
branes and (6) a cytoplasmic tail, possibly involved in translo- 
cation of the protease from one organelle to the other. Addi- 
tionnally, various motifs exist within the protease which may 
help in delineating some of its properties as previously men- 
tioned (see Fig. 1). 
Initial efforts to express furin relied on a recombinant vac- 
cinia virus expression system [26]. Extracts of BSC-40 cells 
infected with the recombinant virus contain two furin transla- 
tion products (90 and 96 kDa) corresponding to the active and 
zymogen form of the enzyme, respectively. It was later deter- 
mined that the 96 kDa form underwent an intramolecular au- 
tocatalytic activation [27] by removal of the pro-region in the 
endoplasmic reticulum [6]. To fully examine furin’s enzymatic 
properties, a secreted form of furin (termed soluble furin), hav- 
ing its trans-membrane domain removed, was constructed 
which facilitated its purification and characterization [27,28]. 
Furin’s enzymatic activity and specificity has been evaluated 
in vitro and in vivo. In vitro assays relying on the use of either 
the shed form of furin [ 141 and/or the soluble furin [28] measure 
the cleavage of various substrates such as the protective antigen 
(PA) precursors or fluorogenic tetrapeptides or using recently 
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developped internally quenched fluorogenic peptidyl substrates 
[28-301. In vivo, by co-expressing various substrate precursors 
along with furin, more than 25 precursors have now been 
cleaved by furin (Table 1) at what has been described as the 
minimal furin recognition site, R-X-X-R, though it has also 
been shown that other members of the convertase family could 
cleave this motif efficiently [31]. In this vein, it has been ob- 
served that characterization of furin enzymatic activity must 
take into account the level of produced enzyme which, in over- 
expression systems, leads to an elevated, non-physiologically 
relevent protease to substrate ratio and thus broadens furin’s 
specificity [32]. Thus, complementation of in vivo studies with 
in vitro enzymatic digestions using purified enzyme and defined 
substrates are necessary to compensate for such discrepancies. 
Overall however, a definition of the processing site used by 
furin permits the inclusion of other determinants that this con- 
vertase accepts for eventual cleavage. Arginine residues in the 
P8, P6, P4, P2 and Pl position relative to the scissile bond 
(R-X-R-X-R-X-X-RI) will in certain cases either be 
critical (PI and P4) or contribute (P2, P6 and P8) to cleavage 
while the + 1 (P,‘) position should not be an amino acid contain- 
ing a hydrophobic aliphatic side chain [33]. For example, the 
use of prorenin as a model substrate in vivo coupled to in vitro 
incubations demonstrated a sequence specificity of RXRX- 
KR > XXRXKR 2 RXRXXR > RXXXKR z XXRXXR for 
furin while XXXXKR and RXXXXR sites were not cleaved 
1331. 
However, in addition to the inherent limitations of the in vivo 
expression system as already noted, the delineation of furin 
enzymatic specificity in vivo is complicated by the fact that, in 
Table 1 
PROTEIN PRECURSORS CLEAVED BY FURIN 
Vim1 gtycupruteins and proteins 
Humm Lylal”egalo”w”s glyropr”tein B 
Measles virus glycoprotem F, 
Newcastle disease virus glycoprokm F. 
Human “nmunodeficxency wms glycoprorein 160 (gpthO) 
Fowl plague (mftuenra A) vies hemaggludnin 
Sindbis virus gpE2 
Mouse mammary t”mor wmr-7 superantigen 
Human paninfluenza vir”( type 3 glycoprotem F, 
Twins 
Receplors 
“ulna” ms”b” pro-receptor 
Hepatacyte growth facrodscatter facror receptor (HGF/SF) 
Plasma proteins 
Human oroalbumm 
Human &mplcment pro-C3 
Human pro-van Willebrand factor 
Human &o-factor tX 
Human vitamm K-dependant pro-factor X 
tturmune and growth factors 
Huma, pro-parathyr”,d related peprldc 
Human pro-pamthyroid hormone 
Mouse pro-,%nerve Srowth factor 
Human pro-rransformmg growth facnr type a 
Human pro-cndathelin-l (PET-I) 
LTHNRTKR’U St” 
ASSRRHKR (i FA 
SGGRRQRR ti FI 
RVVQREKR t, A” 
PSKKREKR u GL. 
GSSGRSKR 6 S” 
GIENRKRR tJ .5-r 
NTDPRTKR u FF 
HHSARVAR 8 MA 
CAGNRVRR 8 S” 
SSNSRKKR fi ST 
FTRHRQPR 1 GW 
PRPSRKRR t, SL 
LTEKRKKR t, ST 
SRGVFFRR u DA 
OPAARRRR il C” 
‘PLSHRSKR U SL 
KILNRPKR ti YN 
QTLERRRR & ;; 
GLSRRLKR 8 A” 
DGKSVKKR t, sI; 
NRTHRSKR 8 SS 
LQSSRHRR t, AL 
WRLRRSKR t CS 
QVAKRTKR ? DIJ 
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Fig. 1. Schematic representation of human furin convertase. 
addition to furin and depending on the cell type used, some 
other convertases are present which might exhibit similar cleav- 
ing patterns and thus contribute to processing of a particular 
precursor; the choice of a suitable cell line then becomes crucial. 
Consequently, a few cellular models have been found and/or 
defined in an effort to eliminate endogenous participation of 
various enzymes. For instance Lo Vb cells, a human colon car- 
cinoma cell line, contain a mutated FUR gene which renders 
the enzyme inactive [34]. However, these cells have elevated 
mRNA levels of PACE4, another convertase, and because of 
similar cleavage specificities observed between furin and 
PACE4 [35] caution must be taken in interpretation of data. 
Another cell type, RPE.40, have demonstrated processing defi- 
ciencies and thus have also been used to study furin-related 
cleavage of specific precursors [36]. 
4. Regulation of furin expression 
Distinct promoters (Pl, PlA and PlB), containing SPl ele- 
ments and a combination of regulated TATA and GC-rich 
regions, have been identified on the FUR gene [37] which may 
explain why multiple mRNA isoforms can be detected; these 
range from 4.0, 4.5, 6.8 and 8.4 kb [19,20] but usually a single 
furin transcript of 4.4 kb is detected in most tissues. Extensive 
studies performed in Drosophila indicate that splicing events 
seem to be occurring in this lower species with variations of 
mRNA levels and size at different larval stages and presence 
of furin in adult female nurse cells, in developing oocytes and 
brain cell soma [19,20]. This suggests a role for furin in develop- 
ment and behaviour. Again in Drosophila two homologous 
genes to human FUR have been identified; three proteins (dfu- 
rin 1, dfurin 1 -CRR, dfurin 1 -X) are generated by the Dfurl gene 
while the Dfur2 gene gives rise to dfurin-2 [38]. Interestingly, 
the biosynthetic fates of these molecules differ, some being 
efficiently converted from zymogen to active enzyme while oth- 
ers are detected as soluble enzymes. 
Although very little information in higher organisms is pres- 
ently available on the control of furin expression, the recent 
observations that the FUR gene contains three distinct promot- 
ers, as above mentioned, may provide clues as to the onset of 
expression or as to different levels of expression detected in 
various cell types and tissues. Thus, a delicate balance of furin 
activity is probably required by all cells since overexpression of 
this enzyme could be toxic to cells or could lead to pathological 
aberrations. In support of this, it has been observed that treat- 
ment of synovial cells and NIH-3T3 cells with a cytokine, TGF- 
/I, resulted in a significant increase in furin transcript levels [39]. 
Since furin is the prime candidate as the proTGF;B cleaving 
enzyme [40], the cytokine may auto-regulate its own convertase 
and hence its conversion rate. 
Regulation or modulation of enzymatic activity can also be 
examined at the post-translational level. Initial efforts to im- 
pede convertase activity relied on the use of active-site-directed 
compounds such as the chloroalkylketones eventhough other 
types of inhibitors have also been prepared [41]. These highly 
reactive compounds, although very useful in biochemical and 
cellular studies suffer from a lack of specificity when, as in the 
case of the convertases, closely related active sites are to be 
targeted. Careful tailoring of the peptidyl sequence may, how- 
ever, improve the specificity of these reagents. An example of 
in vivo convertase inhibition using chloromethylketones was 
the inhibition of furin-derived processing of HIV-l gpl60 to the 
gp120 protein [42]. It was shown that interference of cleavage 
of the glycoprotein by decanoyl-Arg-Glu-Lys-Arg-chlorometh- 
ylketone, not the best of the tetrapeptidyl sequences recognized 
by furin, led to the diminished formation of infectious particles. 
In a similar type of experiment, in vivo processing of proendo- 
thelin-1 was markedly reduced by use of a similar compound, 
decanoyl-Arg-Val-Lys-Arg-chloromethylketone [43]. Failure 
to completely abolish processing of these precursors may be 
due to (1) the efficacy of penetration of the peptide within cells 
or (2) the presence of other convertases not inhibited by the use 
of a specific compound and being able to correctly process the 
precursor, albeit less efficiently or both. 
Protein-based serine protease inhibitors have also been eval- 
uated for their capacity to abolish furin activity. Initially, a 
turkey ovomucoid third domain variant was shown to be inhib- 
itory towards furin [44]. Later, an engineered variant of the 
endogenous elastase inhibitor, the serpin a,-antitrypsin (AT), 
was designed and tested [45]. This protein, called a,-antitrypsin 
Portland (AT-PDX) where the reactive site of the wild type 
protein (Ala355-Ile-Pro-Met358) is replaced with a furin recogni- 
tion site (Arg355-Ile-Pro-Arg358), has a K, 5 of 30 rig/ml (550 PM) 
which compares well to inhibition constants of compounds 
116 
used in therapeutic intervention for inhibition of other types of 
enzymes. This serpin has been recently described in a measles 
virus model to inhibit furin-related processing of fusion 
glycoprotein which resulted in loss of syncitia formation [46] 
and thus may offer novel approaches to antiviral therapy. 
5. Future perspectives 
Because of the ubiquity of furin, the broad distribution and 
shared similarity in specificity to other mammalian convertases 
along with the possible role of furin in processing essential 
cellular factors, inhibition of furin in physio-pathological states 
associated with elevated levels of biologically active factors, is 
somewhat of an equivocal issue. However, a potential target of 
furin inhibitors may be the extracellular membrane form of the 
enzyme. Though no physiological role has been attributed to 
extracellular furin, its involvement and consequently its inhibi- 
tion to convert various bacterial pro-toxins may be addressed 
in vivo in infected animal models. Another interesting aspect 
is the putative furin interacting or binding proteins of the kinase 
or phosphatase class; attempts to identify these proteins are in 
progress. Also, further characterization of the various domains 
of the enzyme, notably the pro-region, the cys-rich region and 
the cytoplasmic tail could be revealing. What is most certain is 
the evergrowing interest in this field of research which will 
undoubtedly lead to multifaceted discoveries. 
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